GENERAL COMMENTARY article

Front. Neurosci., 19 August 2014

Sec. Neuropharmacology

Volume 8 - 2014 | https://doi.org/10.3389/fnins.2014.00254

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

This article is a commentary on:

  1. Advances in non-dopaminergic treatments for Parkinson's disease

    1. Read original article
Sandy Stayte,Sandy Stayte1,2Bryce Vissel,*Bryce Vissel1,2*
  • 1Neuroscience, Neurodegenerative Disorders Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia
  • 2Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia

A Corrigendum on
Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

by Stayte, S., and Vissel, B. (2014). Front. Neurosci. 8:254. doi: 10.3389/fnins.2014.00254

Figure 1 of the article by Stayte and Vissel (2014) contained an error during editing, which we now rectify. In the original Figure 1, the blue arrows representing the GABAergic projections to the LGP originate from the cerebral cortex. However, the blue arrows should be originating from the striatum. We include the updated version of Figure 1 with this correction.

FIGURE 1
www.frontiersin.org

Figure 1. Basal ganglia dysfunction in PD. Diagram representing the normal function of the basal ganglia (Left), the changes occurring in PD (Right), and the site of primary action of therapeutic targets discussed in this review (numbered). Arrows represent the major neurotransmitters of glutamate (green), GABA (blue) and dopamine (red). Relative thickness of the arrows indicates level of activity of neurotransmitter. SNpc, substantia nigra pars compacta; SNr, substantia nigra reticulata; STN, subthalamic nucleus; MGP, medial globus pallidus; LGP, lateral globus pallidus.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Stayte, S., and Vissel, B. (2014). Advances in non-dopaminergic pharmacological treatments of Parkinson's disease. Front. Neurosci. 8:254. doi: 10.3389/fnins.2014.00254

CrossRef Full Text

Keywords: L-dopa, Parkinson's disease, animal models, dopamine, dyskinesias, gene therapy, neurodegeneration, therapeutics

Citation: Stayte S and Vissel B (2014) Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease. Front. Neurosci. 8:254. doi: 10.3389/fnins.2014.00254

Received: 13 July 2014; Accepted: 29 July 2014;
Published online: 19 August 2014.

Edited and reviewed by: Eero Vasar, University of Tartu, Estonia

Copyright © 2014 Stayte and Vissel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence:YnJ5Y2V2aXNzZWxAZ21haWwuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.